Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Centessa Pharmaceuticals (CNTA) over the last 2 years, with Sep 2025 value amounting to $234,000.

  • Centessa Pharmaceuticals' Capital Expenditures rose 588.24% to $234,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $339,000, marking a year-over-year increase of 194.78%. This contributed to the annual value of $34,000 for FY2024, which is 79.88% down from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Capital Expenditures is $234,000, which was up 588.24% from $34,000 recorded in Q3 2024.
  • Centessa Pharmaceuticals' 5-year Capital Expenditures high stood at $652,000 for Q4 2022, and its period low was $10,000 during Q2 2023.
  • In the last 3 years, Centessa Pharmaceuticals' Capital Expenditures had a median value of $38,500 in 2023 and averaged $72,833.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Capital Expenditures plummeted by 95.71% in 2023 and then surged by 588.24% in 2025.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Capital Expenditures stood at $652,000 in 2022, then slumped by 95.71% to $28,000 in 2023, then declined by 20.93% to $34,000 in 2024, then surged by 588.24% to $234,000 in 2025.
  • Its Capital Expenditures was $234,000 in Q3 2025, compared to $34,000 in Q3 2024 and $28,000 in Q4 2023.